The Use of Three-dimensional Visualization Techniques for Prostate Procedures: A Systematic Review

CONTEXT

As an emerging technique, three-dimensional (3D) visualization has become more popular and can facilitate education, training, surgical planning, and intraoperative guidance for prostate cancer surgery.

OBJECTIVE

In this review, we aim to present the impact of 3D printing, virtual reality (VR), and augmented reality (AR) techniques for prostate cancer procedures, specifically prostate biopsy and radical prostatectomy (RP).

EVIDENCE ACQUISITION

A systematic review was performed by two investigators according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) criteria.

EVIDENCE SYNTHESIS

A total of 541 papers were identified in PubMed, Scopus, and Embase. Of these, 53 studies were identified for detailed review and 25 were qualified. Two more studies were identified from the references; thus, 27 studies were finally included in this systematic review. Nine papers reported on the use of 3D reconstructed models, mainly in education/training and intraoperative guidance; nine reported on VR, focusing on simulation training model and intraoperative guidance; and nine reported on AR technique with its best indication for surgical guidance in robotic RP.

CONCLUSIONS

Three-dimensional visualization techniques have gradually been introduced and developed in prostate procedures, and demonstrate potential utility not only for education/training, but also for surgical planning and intraoperative guidance. Prospective studies are needed to demonstrate clinical utility and validation of these technologies.

PATIENT SUMMARY

Despite low-quality evidence, promising signals were identified to demonstrate that three-dimensional visualization could help facilitate prostate procedures, in terms of education/training, surgical planning, and intraoperative guidance. It is still in a very early stage, and more studies need to be conducted to justify its widespread use.

From proteomics to discovery of first-in-class ST2 inhibitors active in vivo

Soluble cytokine receptors function as decoy receptors to attenuate cytokine-mediated signaling and modulate downstream cellular responses. Dysregulated overproduction of soluble receptors can be pathological, such as soluble ST2 (sST2), a prognostic biomarker in cardiovascular diseases, ulcerative colitis, and graft-versus-host disease (GVHD). Although intervention using an ST2 antibody improves survival in murine GVHD models, sST2 is a challenging target for drug development because it binds to IL-33 via an extensive interaction interface. Here, we report the discovery of small-molecule ST2 inhibitors through a combination of high-throughput screening and computational analysis. After in vitro and in vivo toxicity assessment, 3 compounds were selected for evaluation in 2 experimental GVHD models. We show that the most effective compound, iST2-1, reduces plasma sST2 levels, alleviates disease symptoms, improves survival, and maintains graft-versus-leukemia activity. Our data suggest that iST2-1 warrants further optimization to develop treatment for inflammatory diseases mediated by sST2.